IMMUNE RESPONSE TO HIV--NEUTRALIZING ANTIBODY AND VACCINE DEVELOPMENT

在研究免疫监视机制时，手术跟随 人类免疫缺陷病毒(HIV-1)感染，我们有 集中在HIV-1中和抗体上，我们首先 1985年被检测到。在一项有限的调查中，HIV-1感染者 几何均值高的中和抗体效价较低 疾病表现。随后，在儿童艾滋病病例中， 中和抗体与临床稳定状态的关系， 而不是可怜的，被观察到了。在回顾中 HIV-1血清阳性地中海贫血患者的调查 中和抗体也与较好的临床症状有关。 结果。正在进行的HIV-1的长期前瞻性研究- 被感染的人旨在阐明任何保护作用 HIV-1中和抗体。在相关研究中， HIV-1包膜异质性对病毒的诱导和功能的影响 目前正在研究中和抗体。一种HIV-1变异病毒 是通过传播和繁殖一种克隆病毒而获得的 在中和血清存在的情况下分离，表明 特定类型的中和抗体是自然产生的。是否 这种抗体可以引起对变异病毒的免疫选择。 在体内产生并影响疾病进展的仍有待于 下定决心。对该变种的遗传分析表明， 微小的变化是造成其中和性丧失的原因。 进一步的研究将确定重要的表位。其他 鉴定中和表位的方法包括使用 抗病毒gp120的中和性单抗。在……里面 合作研究，各种潜在疫苗的能力 诱导高效价、广谱活性、中和的准备工作 抗体正在检测中。

In studying immune surveillance mechanisms operative following human immunodeficiency virus (HIV-1) infection, we have concentrated on HIV-1 neutralizing antibodies which we first detected in 1985. In a limited survey, HIV-1-infected individuals with high geometric mean neutralizing antibody titers had lesser disease manifestations. Subsequently in pediatric AIDS cases, a relationship of neutralizing antibodies and a stable clinical state, as opposed to a poor one, was observed. In a retrospective investigation of HIV-1-sero-positive thalassemia patients, neutralizing antibodies also were associated with a better clinical outcome. Ongoing long-term prospective studies of HIV-1- infected individuals are aimed at elucidating any protective role of HIV-1 neutralizing antibodies. In related studies, the effect of HIV-1 envelope heterogeneity on the elicitation and function of neutralizing antibodies is being pursued. An HIV-1 variant virus was obtained by transmitting and propagating a cloned virus isolate in the presence of a neutralizing serum, indicating that type-specific neutralizing antibodies occur naturally. Whether such antibodies can cause immune selection of mutant viruses arising in vivo and influence disease progression remains to be determined. Genetic analysis of the variant has shown that a minor change was responsible for its loss of neutralizability. Further studies will pinpoint important epitopes. Other approaches for identification of neutralizing epitopes include use of a neutralizing monoclonal antibody to the viral gp120. In collaborative studies, the ability of various potential vaccine preparations to elicit high-titer, broadly reactive, neutralizing antibodies is being examined.